WEDI to advance genomic data exchange with new workgroup

The Workgroup for Electronic Data Interchange (WEDI) is developing a workgroup focused on Genomic Data Exchange as well as the appointment of three co-chairs to lead the group as it evaluates and outlines a common industry vision for genomic data in healthcare.

“With all of the latest advances in genomic sequencing, profiling, testing and phenotyping, the healthcare industry is quickly entering a completely new era of personalized medicine. This progress will require more advanced health information technology, capable of rapidly accessing, exchanging and processing information to fully inform diagnostic, treatment and prevention decisions at the point of care,” said Devin Jopp, EdD, president and CEO of WEDI. “It is important that WEDI, as the leading authority on health IT and health information exchange, bring this issue to the forefront and investigate not only how to build a national infrastructure to support this genomic data, but how to create seamless workflows to enhance the delivery and coordination of care.”

Katherine Johansen Taber, PhD, director of the American Medical Association’s Personalized Medicine Program; Adam Scott, vice president of consumer clinical strategy at Aetna; and Grant Wood, senior IT strategist for Intermountain Healthcare’s Clinical Genetics Institute will serve as co-chairs of the WEDI Genomic Data Exchange Workgroup.

The Genomic Data Exchange Workgroup will further evaluate and create a common industry vision and roadmap on how to incorporate genomic data into the U.S. healthcare system. 

The newly formed workgroup emerged from an initial investigation into a wide range of genomic information exchange issues including genomic data formats, exchange, privacy controls, security, storage, management, governance, care coordination and payer-provider collaboration.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.